Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction
2014; Massachusetts Medical Society; Volume: 371; Issue: 11 Linguagem: Inglês
10.1056/nejmoa1407024
ISSN1533-4406
AutoresGilles Montalescot, Arnoud W.J. van ’t Hof, Frédéric Lapostolle, Johanne Silvain, Jens Flensted Lassen, Leonardo Bolognese, Warren J. Cantor, Ángel Cequier, Mohamed Chettibi, Shaun G. Goodman, Christopher Hammett, Kurt Huber, Magnus Janzon, Béla Merkely, Robert F. Storey, Uwe Zeymer, Olivier Stibbe, Patrick Ecollan, Wim M.J.M. Heutz, Eva Swahn, Jean‐Philippe Collet, Frank F. Willems, Caroline Baradat, Muriel Licour, Anne Tsatsaris, Éric Vicaut, Christian W. Hamm,
Tópico(s)Coronary Interventions and Diagnostics
ResumoThe direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI). Whether prehospital administration of ticagrelor can improve coronary reperfusion and the clinical outcome is unknown.
Referência(s)